key: cord-0875364-vo0hjiyi authors: Akturk, Hacer; Tanyildiz, Murat; Erbey, Fatih; Tasdemir, Mehmet; Celikyurt, Aydın; Gonen, Emel; Bilge, Ilmay title: Macrophage Activation Syndrome in a Child with Juvenile Idiopathic Arthritis Secondary to SARS-CoV-2 date: 2021-05-24 journal: J Trop Pediatr DOI: 10.1093/tropej/fmab049 sha: a1e586c24aa2e70c124f764aacc7be3d175d8e6b doc_id: 875364 cord_uid: vo0hjiyi Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic affecting many countries and millions of people. Physicians has encountered some rare and challenging cases related to SARS-CoV-2, a novel virus with still many unknowns. In order to share our experience of a such clinical picture, we present here a child with SARS-CoV-2 induced macrophage activation syndrome in the setting of juvenile idiopathic arthritis. 2 The authors have no example conflicts of interests to disclose. Funding/Support: No funding was secured for this study. Informed consent was received from the legal guardians of the child. Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 3 Summary: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic affecting many countries and millions of people. Physicians has encountered some rare and challenging cases related to SARS-CoV-2, a novel virus with still many unknowns. In order to share our experience of a such clinical picture, we present here a child with SARS-CoV-2 induced macrophage activation syndrome in the setting of juvenile idiopathic arthritis. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 4 Introduction: The pandemic of coronavirus disease-19 (COVID-19) , caused by a new coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused significant morbidity and mortality worldwide. 1 An immune mediated hyperinflammation in lungs seems to play an important role in development of acute respiratory distress syndrome, the main reason for morbidity and mortality in COVID-19. 2 Some laboratory parameters, highly suggestive of macrophage activation syndrome (MAS)/secondary haemophagocytic lymphohistiocytosis (sHLH) are also elevated in a subgroup of severe COVID-19 pneumonia cases. In those patients, a mimicry of autoimmune diseases may be seen including fever, arthralgia, myocarditis, cytopenias, coagulopathy and a cytokine storm similar to MAS. 3 Secondary haemophagocytic lymphohistiocytosis occurs as a result of an exaggerated immunological reaction caused by different inciting conditions like infection, malignity or autoimmune diseases. MAS, as a form of sHLH, is usually associated with autoimmune rhemuatic disorders. It develops in approximately 7% of patients with juvenile idiopathic arthritis (JIA). 4 A broad clinical spectrum affecting different organ systems may be seen over the course of COVID-19. Different clinical profiles may lead to diagnostic and therapeutic dilemmas in some complicated and overlapping conditions. Here, we present such a case; a child who developed MAS during in-hospital treatment of presumed septic arthritis with a differential diagnosis of JIA, and turned out to be SARS-CoV-2 positive. A 10 year old boy had sufferred from right ankle pain, swelling and limping. After antibiotic therapy in another hospital, his complaints had partially resolved. Six weeks after the operation, he was admitted to our hospital with recurrence of pain, swelling of the right ankle, fever and refusal to walk. Swelling, redness, warmth and pain were noticed not 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 5 only on right ankle but also more manifestly on left knee. Acute phase reactants were increased (Table 1) . Magnetic resonance imaging showed findings of arthritis and synovitis on affected joints. Aspiration of synovial fluid revealed 25500 leukocytes/microL with 86% of neutrophils. Although the overall clinical picture had features indicating a diagnosis of JIA, septic arthritis could not be excluded. Thence, an arthrotomy was performed for drainage and aspiration. No bacterial growth was observed on culture. Pathologic examination revealed chronic synovitis. Intravenous antibiotics was commenced, fever subsided, acute phase reactants decreased. The plan was 4 weeks of antibiotics for presumed septic arthritis, together with arrangement of treatment regarding JIA. On the 10 th day of hospitalization, he developed fever without any localizing signs and symptoms. No recurrence of arthralgia/arthritis was observed. Blood and urine cultures remained sterile. Viral serologic tests including Epstein barr virus and cytomegalovirus remained negative. Although there is no contact history, due to ongoing pandemic, a nasopharyngeal swab was taken for testing SARS-CoV-2 PCR on 4 th day of fever and found to be positive. Laboratory testing showed newly developed cytopenias, increased acute phase reactants, transaminases and trigylceride levels ( Table 1) . Bone marrow aspiration revealed abundant hemophagocytosis ( Figure 1 ). Based on these findings, the patient was diagnosed as MAS in the setting of JIA, secondary to SARS-CoV-2 infection. Thorax CT, echocardiography and cardiac enzymes were normal. There were no signs and symptoms related to involvement of gastrointestinal, cutaneous and cardiovascular system. Favipiravir (loading dose: 1600 mg twice daily, maintenance dose:600 mg twice daily) was commenced for 5 days due to SARS-CoV-2 positivity in a child with MAS. For the treatment of MAS, 1 gr/kg/day intravenous immunoglobulin and plasma exchange were administered one after the other for 5 days and 10 mg/m 2 /day dexamethasone was started. The patient's condition improved and all abnormal laboratory parameters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 6 returned to normal levels. Steroid treatment was continued as oral methylprednisolone and methotrexate was planned as next step in the treatment of JIA. Macrophage activation syndrome may be the first manifestation of sJIA, but it may also be seen during the course of an established JIA. 5 Viral infections are known triggers of MAS. [5] [6] [7] They can also execarbate an episode of MAS in patients with known autoimmune diseases. 6, 7 Similarly, we believe that our patient with JIA has experienced a MAS episode, triggered by a viral infection, namely SARS-CoV-2. A hyper-inflammatory state is known to occur in some COVID-19 patients. An exaggarated immune response resembling MAS/sHLH exacerbates the condition, which may end with mortality. 8 In COVID-19, this picture generally develops in conjuction with severe lung affection. 2 The patients with cytokine storm also have a severe COVID-19 pneumonia. This is 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 His clinical picture, as detailed previously, was compatible with a MAS episode rather than MIS-C. Since there are conflicting evidence and recommendation surrounding high dose corticosteroid use especially in the early acute phase of COVID-19 infection, high dose steroid was not used in this case. 14 We made an immunomodulatory treatment plan so colled zipper method, which was previously used in the treatment of other immune-mediated diseases. 15 We think that early initiation of a comprehensive immunomodulatory treatment has helped to achieve a total clinical and laboratory response in a short time. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 8 autoimmune disease. SARS-CoV-2 screening may be considered in flares of autoimmune diseases. We need guidance of accumulating experience and evidence regarding immunomodulatory and antiviral treatment options in such cases. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 A new coronavirus associated with human respiratory disease in China The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndromelike disease Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases Macrophage Activation Syndrome Hepatitis A-associated Macrophage Activation Syndrome in children with Systemic Juvenile Idiopathic Arthritis: Report of 2 cases Hepatitis A causing a second episode of virus-associated haemophagocytic lymphohistiocytosis in a patient with Still's disease Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes ng/mL), -6980 ng/mL IL-6 (N:1,5-7 pg/mL). -23.6 pg/mL D dimer (N:<500 ug/L)